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 Many parenchymal renal diseases charac-
terized by podocyte injury result from the 
interaction of genetic and environmental 
factors. 1 Collapsing glomerulopathy (CG) 
is no exception. Since its first clinical-
pathologic descriptions almost three dec-
ades ago, two general clinical correlates 
suggesting causality for CG continue to be 
strengthened: its predilection for patients 
of African descent; and its occurrence in 
conditions — many environmentally 
derived — with preceding immune 
activation, particularly T-helper type 1 
(; 1)-polarizing disorders. 2 Experimental 
evidence that the genetic susceptibilities 
of the former may be unmasked by the 
latter is only now forthcoming. 
 In this vein, a new study by Chan  et al. 3 
(this issue) makes an exciting advance-
ment toward understanding genetic 
susceptibilities for CG. ; e success of their 
multistep approach starts historically with 
the oM en serendipitous outcomes of reverse 
genetics in mice. In the late 1980s, the labo-
ratories of Malcolm Martin and Abner Not-
kins at the US National Institutes of Health 
collaboratively used transgenic technology 
to create FVB / N-strain mice bearing subg-
enomic human immunode$ ciency virus-1 
(HIV-1) proviral transgenes in efforts 
toward a rodent model of AIDS. Although 
human AIDS-like immunode$ ciency was 
not observed in the many transgenic found-
ers produced, a few curiously and unexpect-
edly developed renal disease strikingly 
similar to CG in HIV-infected patients. 4 
 Using the FVB / N Tg26 line resulting 
from this early discovery, 4 forward 
genetic techniques were then employed to 
map genetic susceptibility loci for CG. 5 
Cross-breeding of FVB / N Tg26 mice 
with several di3 erent inbred strains of mice 
showed a considerable strain-dependent 
variation in the severity of CG in F 1 prog-
eny. To identify genetic susceptibility loci 
present in one such strain, CAST, a mouse 
genome-wide analysis of linkage to 
increased severity of CG, was performed 
on B 1 progeny from backcrossing of 
(FVB / N Tg26  × CAST)F 1 with FVB / N 
Tg26 mice. ; is mapped a genetic suscep-
tibility locus, termed  HIVAN1 , to CAST 
mouse chromosome 3A1 – A3. 
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 Now, Chan  et al. again combine reverse 
and forward genetic techniques to provide 
con$ rmatory evidence that  HIVAN1 likely 
contains genetic modi$ ers of CG. 3 Starting 
with the B 1 progeny noted above, back-
crossing with FVB / N mice was continued 
another nine times to retain and passage 
 HIVAN1 from the CAST strain while at the 
same time enriching for the FVB / N genetic 
background. Clinical analyses of subse-
quent intercrosses with FVB/N Tg26 mice 
showed that those Tg26 progeny bred con-
genic for HIVAN1 had signi$ cantly earlier 
onset and severity of CG when compared 
with those lacking HIVAN1. ; en, using 
FVB/N mice congenic for HIVAN1 for 
meiotic mapping and linkage to increased 
severity of CG, HIVAN1 was further re$ ned 
to an interval containing 126 candidate sus-
ceptibility genes. Of those annotated, 22 
contain single-nucleotide polymorphisms 
that di3 er between the FVB / N and CAST 
strains, already o3 ering candidate genetic 
modi$ ers for future study. 
 ; is multistep approach of combining 
forward and reverse genetics toward 
identifying and con$ rming susceptibility 
genes was recently successful in another 
model of CG. Discovered serendipitously 
by Mary Lyon over 3 decades ago,6 
CS7BL/6 kd/kd mice are susceptible to 
CG due to a genetically acquired mito-
chondriopathy.7  Mapping through for-
ward genetics showed the genetic lesion 
in this model to be a missense mutation 
in the  Pdss2 gene, encoding an enzyme 
required for mitochondrial coenzyme Q 
biosynthesis; subsequent reverse genetics 
to develop targeted cell-speci$ c mutants 
demonstrated that loss of  Pdss2 in podo-
cytes alone determined the susceptibility 
for CG. 8 ; e requirement of environmen-
tal factors to unmask this susceptibility 
was discovered when germ-free but not 
speci$ c-pathogen-free  kd / kd mice were 
found to be protected from developing 
CG. 9 Intriguingly, under germ-free con-
ditions, commensals needed for homeo-
static Th1 development are absent, 
resulting in default systemic ; 2 skew-
ing; 10 this lends credence to the clinical 
correlate suggesting that ; 1 states, even 
 ‘ clinically silent ’ ones, may precipitate CG 
in susceptible patients. 2 
 Interrogation of how environmental fac-
tors and the candidate genetic modi$ ers of 
CG identi$ ed by Chan  et al. 3 play a patho-
genic role in the setting of HIV infection, 
however, is likely to be more complex ( Fig-
ure 1 ). For example, the infected host cell ’ s 
environment markedly in5 uences infec-
tion with HIV and whether HIV enters 
latency or becomes transcriptionally 
active, 11 and host genetic modi$ ers might 
alter environmentally induced changes in 
the HIV life cycle. During productive 
infection, HIV gene products can co-opt 
and hijack host molecular pathways con-
trolling proliferation, apoptosis, and 
in5 ammation, 12 and host genetic modi$ -
ers may synergistically activate or 
amplify these pathways. Alternatively, host 
genetic modifiers may act sequentially 
before or after any pathogenic role of 
HIV to precipitate or accelerate CG. 
Indeed, any of these and many other 
combinations of possibilities exist, and 
deciphering it all may require a more sys-
tems-biology approach to host – pathogen 
interactions. 13 In any respect, research 
into the genetic susceptibilities for 
CG is moving beyond serendipity, and the 
time-consuming approach of Chan  et al. 3 
that is needed to provide answers is note-
worthy. 
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 Figure 1  | The interplay of forward and reverse genetics in identifying genetic susceptibilities for collapsing glomerulopathy. Environmental 
factors may unmask genetic susceptibilities to influence the onset or progression of collapsing glomerulopathy. (Histopathology images adapted from 
ref. 9 with permission.) 
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Hence, reports published in 1998 of an asso-
ciation between serum phosphate levels and 
mortality based on data from the United 
States Renal Data System 1 resulted in an 
explosion of interest and research. Despite an 
almost complete absence of con$ rmatory 
data from interventional randomized con-
trolled trials, the link seemed to $ t intuitively 
in the minds of most clinicians, and as a 
result the quest for the  ‘ ideal phosphate 
binder ’ has accelerated in a way that would 
never have been envisaged a decade ago. 
Lanthanum carbonate is a product of this 
quest, but because previously it had been 
thought to have no medicinal applications, 
very little was known of its pharmacokinet-
ics, and reasonable concerns have been raised 
about possible deposition and mechanisms 
of elimination. Sadly, these concerns have 
been ampli$ ed by the marketing strategies of 
other phosphate binder manufacturers, so 
that the injection of some elegant science 
into the debate is both timely and welcome. 
 Bervoets  et al. 2 (this issue) demonstrate 
masterly use of advanced basic-science 
techniques to investigate and clarify a 
clinical conundrum. A combination of 
three techniques, probably not familiar to 
most nephrologists, was used to localize 
lanthanum to the lysosomes in the liver of 
rats. First lanthanum was co-mapped 
with iron with the synchrotron particle 
accelerator in Grenoble to induce X-ray 
microfluorescence; then transmission 
electron microscopy and $ nally electron 
energy-loss spectroscopy enabled identi-
$ cation and subcellular localization of 
lanthanum to the lysosomes. 
 Lysosomes are organelles generated by 
the Golgi apparatus that appear in the cyto-
plasm as bodies bounded by a single mem-
brane. ; ey can contain over 30 di3 erent 
hydrolytic enzymes, and material requiring 
digestion is $ rst deposited within them. In 
addition, they can take up antigens and 
metals, including copper and iron. ; is 
study appears to have also identi$ ed the 
liver lysosomes as the route of transport for 
lanthanum, from serum to bile and, there-
aM er, excretion via the intestine. ; e other 
particularly intriguing aspect of this study 
is the demonstration that intestinal uptake 
of lanthanum appears to be increased in 
rats with chronic kidney disease compared 
to those with normal kidney function. ; e 
difference is relatively small but leads 
the authors to speculate that it may be 
related to increased intestinal  ‘ permeability, ’ 
which has previously been demonstrated 
in uremic rats. ; e mechanism by which 
intestinal permeability may be increased 
is not known, but Bervoets  et al. 2 focus on 
the possibility that it is related to an in5 am-
matory state. However, it is also known that 
both zinc de$ ciency 3 and hyperprolactine-
mia, 4 neither of which is uncommon in 
patients on dialysis, modulate intestinal 
permeability, and there may also be other 
mechanisms at play. 
 Intestinal transporters of dietary  ‘ essen-
tial metals, ’ including zinc transporters, 
divalent metal transporter 1 (DMT1), fer-
roportin, and calcium transporter 1, have 
been identi$ ed in mammals. ; ese trans-
porters are upregulated or downregulated 
according to the host ’ s essential-metal 
nutritional status. For example, iron 
depletion is thought to upregulate mRNA 
encoding functional DMT1, an apical iron 
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 Ten years ago, mineral metabolism in dialy-
sis patients was of limited interest to the 
nephrology community, perhaps because the 
e3 ect of its derangement was thought to be 
similarly limited — to the skeleton. However, 
cardiac and cerebral vascular disease is 
responsible for the majority of deaths in 
patients with chronic kidney disease, and 
deposition of phosphate and calcium can be 
seen radiologically in the blood vessels of 
many dialysis patients. We know that the 
5 – year survival of patients around the age of 
60 years and on dialysis is worse than that of 
patients with breast cancer and colon cancer, 
and only marginally better than that of 
patients with ovarian cancer ( Table 1 ). 
see original article on page 389
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 Mineral metabolism in chronic kidney disease is attracting intense 
interest and unprecedented levels of research. The pharmaceutical 
industry has responded by developing various new agents. Bervoets 
 et al. report the use of an unusual combination of basic-science 
techniques to increase understanding of the kinetics of one such agent —
 lanthanum carbonate — in the gastrointestinal tract and liver. However, 
do we need to answer more fundamental clinical questions before we 
can definitively identify the role of similar new and expensive drugs? 
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